Abstract

Triple-negative breast cancer (TNBC) is the most aggressive cancer type that tests negative for progesterone, estrogen, and HER2 protein receptors. Therefore, TNBC is unlikely to respond either to drugs that target HER2 receptors or to hormonal therapy drugs. In the present study, 2D-QSAR model was developed to predict the inhibitory concentration (IC50) of terpene derivatives against human breast cancer metastatic cell line MDA-MB231, using V-Life MDS v4.5, module. The model was developed using the forward stepwise multiple linear regression method, with a regression coefficient (r2) of 0.86, and a cross-validated r2 (q2) of 0.8448. Molecular descriptors namely electronegativity (Epsilon-3), carbon atoms separated through five bond distances (T_C_C_5), Sum of Electrotopological state indices of –CH2 group (SssCH2count), Dipole moment of coordinate-z (Zcomp Dipole), and Distance between highest positive and negative electrostatic potential on van-der Waals surface area (Most +ve & -ve Potential Distance) were found to be the most potent contributing chemical descriptors for cytotoxicity against TNBC MDA-MB231 cell line. Additionally, binding affinities and interaction patterns revealed that the proposed compounds exhibit good binding affinities and substantial stability with c-Met-and β-tubulin receptors, as assessed by docking studies. Molecular dynamics simulations (100 ns) and binding free energy calculations were also performed using the MMGBSA method. The pharmacokinetic and eADME/T analysis of predicted compounds were assessed through Discovery Studio software. These findings may be of immense importance in the optimization and development of dual inhibitory potent anti-cancer inhibitors against the MDA-MB231 TNBC cell line. Moreover, this novel QSAR based prediction model/method is implemented in R-package and software tool developed for virtual screening purposes and available online for download through the public repository GitHub.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.